Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial

Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment

“…In total, 70 (71%) were based on patients from tertiary care institutions, 5-74 13 (13%) were population-based studies [75][76][77][78][79][80][81][82][83][84][85][86]87 9 (9%) were based on the patients of a single surgeon, 9,22,36,[88][89][90][91][92][93] and 5 (5%) were results from randomized trials. [94][95][96][97][98] Only one out of the five randomized trials compared treatment to CM. 97 This is important to note because the comparison of treatment to CM is necessary in order to estimate the relative or excess risk following treatment.…”

“…Based on a randomized trial, the overall risk of Grade 1 and Grade 2 rectal toxicity after ERT was 47 and 10%, respectively (the total risk of mild symptoms was 57% as shown in Table 3); the risk after CRT was slightly lower (40 and 7%, respectively, total risk of mild symptoms 47% as shown in Table 3). 98 However, more severe symptoms (over RTOG grade 2, stool incontinence, rectal bleeding and/or perforation) may also occur in up to approximately 40% of patients following ERT or CRT (Table 3). After BRT, the risk of mild bowel symptoms is generally less than 20% in the first year of treatment; more severe long-term bowel symptoms are also probably not common.…”

Association of DNA Repair and Steroid Metabolism Gene Polymorphisms with Clinical Late Toxicity in Patients Treated with Conformal Radiotherapy for Prostate Cancer

“…Estimates of the risk of late bladder and rectal toxicity after 3-DCRT vary from 7% to 38%, depending upon the time interval reported (2,4,5). The best strategy to identify patients who are potentially at risk for late radiotherapy toxicity before undergoing 3-DCRT for prostate cancer is currently unknown.…”

Re: Ulike retningslinjer for behandling av prostatakreft

“…Dette er vist i randomiserte studier for anorektale bivirkninger., men urinveistoksisiteten er ikke redusert i samme grad. (Dearnaley et al, 2005,Koper et al, 2004.…”

“…Betydning av dose og volumer på bivirkninger ved strålebehandling av prostatakreft har vaert vist i mange studier (Catton et al, 2002,Dearnaley et al, 1999,Dearnaley et al, 2005,Greco et al, 2003,Koper et al, 1999,Koper et al, 2004,Rancati et al, 2004,Schultheiss et al, 1997. I randomiserte doseskaleringsstudier har det vaert vist en økning i genitourethrale og gastrointestinale bivirkninger ved bruk av standard fraksjoneringsregimer (ikke hypofraksjonert).…”